SLC5A2 and chronic kidney disease: The data on the safety and efficacy of SGLT2 inhibitors used in non-diabetic patients with low values of eGFR come from four heart failure trials (EMPEROR-Reduced, EMPEROR-Preserved, DAPA-HF, DELIVER) and two CKD trials (DAPA-CKD and EMPA-KIDNEY).